Clinica Onco Star

São Paulo 04543-000

1 studies enrolling now · 3 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, Crohn's Disease, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Metastatic Breast Cancer, PIK3CA Mutation

Studies at this site

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling